FrancophonIA/ELRC3.0 huggingface dataset:
English: Fipronil works on channels in the cells of the nervous system of ticks and fleas, blocking the transfer of ions in and out of cells,
Estonian: Fiproniil mõjutab puukide ja kirpude närvirakkude kanaleid, blokeerides ioonide kandumist rakkudesse ja välja; see muudab parasiitide kesknärvisüsteemi tegevuse juhitamatuks ja parasiidid hävivad.
English: How has Certifect been studied?
Estonian: Kuidas Certifecti uuriti?
English: What benefit has Certifect shown during the studies?
Estonian: Milles seisneb uuringute põhjal Certifecti kasulikkus?
English: Influenza virus surface antigens*, inactivated: A/Vietnam/1194/2004 (H5N1) - like strain used (NIBRG-14) 7.5 micrograms** per 0.5 ml dose * propagated in eggs ** expressed in microgram haemagglutinin.
Estonian: Gripiviiruse pinnaantigeenid*, inaktiveeritud: kasutatud A/Vietnam/1194/2004 (H5N1) sarnast tüve (NIBRG-14) 7,5 mikrogrammi** 0,5 ml annuse kohta * kasvatatud kanamunades ** väljendatud hemaglutiniini mikrogrammides.
English: Adjuvant MF59C.1 containing: squalene
Estonian: Adjuvant MF59C.1 sisaldab:
English: Packaging Content (concentration) Package size
Estonian: Pakendi sisu Pakendi suurus
English: The recommended dose is four capsules three times a day (a total of 12 capsules a day).
Estonian: Soovitatav annus on 4 kapslit kolm korda ööpäevas (kokku 12 kapslit ööpäevas).
English: The full EPAR for Victrelis can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Victrelise kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: If taken without food the medicine may not work properly.
Estonian: Kui seda manustatakse ilma toiduta, võib ravimi toime nõrgeneda.
English: However, the Committee decided that the medicine's benefits outweighed its risk and recommended that it be granted marketing authorisation.
Estonian: Komitee otsustas siiski, et ravimi kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
English: What measures are being taken to ensure the safe use of Victrelis?
Estonian: Mis meetmed võetakse, et tagada Victrelise kasutamise ohutus?
English: The main measure of effectiveness was the number of patients who had no detectable virus in their blood 24 weeks after the end of the treatment and could therefore be
Estonian: Efektiivsuse põhinäitaja oli nende patsientide arv, kelle veres ei tuvastatud 24 nädalat pärast ravi lõppu viirust ning keda võis seega pidada tervenenuks.
English: These medicines can be harmful at high levels in the blood and it is important to avoid taking them when taking Victrelis.
Estonian: Nende ravimite suur sisaldus veres võib olla kahjulik ning Victrelise kasutamise ajal ei tohi neid võtta.
English: Why has Victrelis been approved?
Estonian: Miks Victrelis heaks kiideti?
English: The European Commission granted a marketing authorisation valid throughout the European Union for
Estonian: Euroopa Komisjon andis Victrelise müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 18. juulil
English: Victrelis can slow down the rate at which certain medicines are broken down in the liver.
Estonian: Victrelis võib aeglustada teatud ravimite lagunemist maksas.
English: When the enzyme is blocked, the virus does not replicate normally and this slows down the rate of replication, helping to eliminate the virus.
Estonian: Pärast ensüümi blokeerimist ei paljune viirus enam normaalselt ning nakkuse levik aeglustub, mis aitab viiruse nakkust ravida.
English: Victrelis is to be used in patients with compensated liver disease who have not been treated before or whose previous treatment has failed.
Estonian: Victrelist kasutatakse kompenseeritud maksahaigusega patsientidel, kes ei ole varem ravi saanud või kelle haigus ei ole allunud varasemale ravile.
English: This is a summary of the European public assessment report (EPAR) for Victrelis.
Estonian: See on ravimi Victrelis Euroopa avaliku hindamisaruande kokkuvõte.
English: It should be taken with food (a meal or light snack).
Estonian: Victrelist peab võtma toiduga (eine või kerge suupistega).
English: In both studies Victrelis was compared with placebo (a dummy treatment).
Estonian: Mõlemas uuringus võrreldi Victrelist platseeboga (näiv ravim).
English: Victrelis is a medicine that contains the active substance boceprevir.
Estonian: Victrelis on ravim, mis sisaldab toimeainena botsepreviiri.
English: In the study of previously untreated patients, 66% of patients who received Victrelis for 44 weeks (242 out 366) were cured compared with 38% of those who received placebo (137 out of 363).
Estonian: Varem ravimata patsientide uuringus tervenes Victrelist 44 nädala jooksul saanud patsientidest 66% (242 patsienti 366st) ning platseebot saanud patsientidest 38% (137 patsienti 363st).
English: Victrelis was also shown to be effective in some patients whose treatment was shortened following blood tests in which the virus could no longer be detected in their blood.
Estonian: Samuti oli Victrelis uuringute põhjal efektiivne mõnel patsiendil, kelle ravi lõpetati varem, sest vereanalüüsidega ei tuvastatud nende veres enam viirust.
English: What is the risk associated with Victrelis?
Estonian: Mis riskid Victrelisega kaasnevad?
English: The other most common side effects with Victrelis are fatigue (tiredness), nausea (feeling sick), headache and dysgeusia (taste disturbances).
Estonian: Muud Victrelise kõige sagedamad kõrvalnähud on väsimus, iiveldus, peavalu ja düsgeusia (maitsehäired).
English: The company that makes Victrelis will ensure that all doctors expected to prescribe the medicine are provided with an educational pack with detailed information on the medicine, including information on the risk of anaemia and other side effects.
Estonian: Victrelise tootja varustab kõik ravimit määravad arstid teabepakmega, mis sisaldab üksikasjalikku teavet ravimi kohta, sealhulgas aneemia ja muude kõrvalnähtude tekkeriski kohta.
English: It must not be used in patients with autoimmune hepatitis (hepatitis caused by an immune disorder) or in pregnant women.
Estonian: Seda ei tohi kasutada autoimmuunse hepatiidiga (immuunhäirest põhjustatud hepatiit) patsiendid ega rasedad.
English: All patients also received peginterferon alfa and ribavirin.
Estonian: Kõik patsiendid said ka alfapeginterferooni ja ribaviriini.
English: For more information about treatment with Victrelis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Victrelisega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: How does Victrelis work?
Estonian: Kuidas Victrelis toimib?
English: Victrelis must not be used in people who are hypersensitive (allergic) to boceprevir or any of the other ingredients.
Estonian: Victrelist ei tohi kasutada patsiendid, kes on botsepreviiri või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: For a list of these medicines see the summary of product characteristics (also part of the EPAR).
Estonian: Nende ravimite loetelu on ravimi omaduste kokkuvõttes (samuti Euroopa avaliku
English: What benefit has Victrelis shown during the studies?
Estonian: Milles seisneb uuringute põhjal Victrelise kasulikkus?
English: For more information on how to use Victrelis, including its combination with peginterferon alfa and ribavirin and the length of treatment, see the summary of product characteristics (also part of the EPAR).
Estonian: Üksikasjalik teave Victrelise kasutamise kohta, sealhulgas Victrelise, alfapeginterferooni ja ribaviriini kombinatsioonravi ja ravi kestuse kohta on ravimi omaduste kokkuvõttes (samuti Euroopa avaliku hindamisaruande osa).
English: Two main studies involving 1,099 previously untreated and 404 previously treated patients with chronic hepatitis C genotype 1 infection and compensated liver disease were carried out.
Estonian: Korraldati kaks põhiuuringut C-hepatiidi I genotüübi kroonilise infektsiooniga ja kompenseeritud maksahaigusega patsientidel, kellest 1099 ei olnud ja 404 olid varem ravi saanud.
English: In a second study in patients in whom previous treatment had failed, the cure rate was 67% (107 out of 161) for patients who received Victrelis for 44 weeks compared with 21% (17 out of 80) for those
Estonian: Teises uuringus, kus vaadeldi patsiente, kellele ei olnud varasem ravi mõjunud, tervenes Victrelist 44 nädala jooksul saanud patsientidest 67% (107 patsienti 161st) ning platseebot saanud patsientidest
English: Victrelis in combination with peginterferon alfa and ribavirin can lead to a higher rate of anaemia (low red blood cell counts) than is seen in treatment with peginterferon and ribavirin alone.
Estonian: Victrelis kombinatsioonis alfapeginterferooni ja ribaviriiniga võib tekitada aneemia (vere punaliblede vähesus) suuremat esinemissagedust kui üksnes alfapeginterferooni ja ribaviriiniga toimuva ravi korral.
English: The CHMP noted that Victrelis in combination with peginterferon alfa and ribavirin significantly increases the number of patients cured of chronic hepatitis C infection.
Estonian: Inimravimite komitee märkis, et kombinatsioonis alfapeginterferooni ja ribaviriiniga suurendab Victrelis oluliselt kroonilisest C-hepatiidi infektsioonist paranenud patsientide arvu.
English: It blocks an enzyme called HCV NS3 protease, which is found on the hepatitis C virus of the type 1 genotype and is involved in the virus's replication.
Estonian: Victrelise toimeaine botsepreviir on proteaasiinhibiitor, mis blokeerib C-hepatiidi I genotüübi viiruses leiduva ja viiruse paljunemisel osaleva ensüümi HCV NS3 proteaasi.
English: The effects of Victrelis were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Victrelise toimet muude katsetega.
English: The main increase in side effects seen when adding Victrelis to treatment was anaemia.
Estonian: Seoses kõrvalnähtudega täheldati Victrelise lisamisel aneemiajuhtude arvu suurenemist.
English: The patients must first take peginterferon alfa and ribavirin for four weeks, after which they will add Victrelis to the treatment for up to 44 weeks, depending on several factors such as the patient's previous treatment and results of blood tests during treatment.
Estonian: Esmalt peavad patsiendid 4 nädala jooksul võtma alfapeginterferooni ja ribaviriini, seejärel võtavad nad 44 nädala jooksul lisaks Victrelist.
English: Victrelis was effective at curing patients with chronic hepatitis C genotype 1 infection who were also treated with peginterferon alfa and ribavirin.
Estonian: Victrelis oli efektiivne C-hepatiidi I genotüübi kroonilise infektsiooniga patsientide ravimisel kombinatsioonis alfapeginterferooni ja ribaviriiniga.
English: Compensated liver disease is when the liver is damaged but is
Estonian: Kompenseeritud maksahaigus tähendab, et haige maksa
English: This was an important improvement on results seen with only peginterferon alfa and ribavirin together.
Estonian: See on oluliselt parem tulemus kui üksnes alfapeginterferooni ja ribaviriiniga toimuva ravi korral.
English: For the full list of all side effects reported with Victrelis, see the
Estonian: Victrelise kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Treatment with Victrelis should be started and monitored by a doctor experienced in managing chronic
Estonian: Ravi Victrelisega peab alustama kroonilise C-hepatiidi ravis kogenud arst ja ravi peab toimuma tema
English: It is available as capsules
Estonian: Seda turustatakse kapslitena (200 mg).
English: Victrelis is used to treat adults with chronic (long-term) hepatitis C genotype 1 (a disease of the liver due to infection with the hepatitis C virus) in combination with two other medicines, peginterferon alfa
Estonian: Victrelist kasutatakse kombinatsioonis alfapeginterferooni ja ribaviriiniga I genotüübi C-hepatiidi kroonilise (pikaajalise) nakkuse (C-hepatiidi viiruse teatud tüübi nakkusest põhjustatud maksahaigus)
English: These should be submitted to the National Competent Authorities: Within 1 month of the Commission decision.
Estonian: 1 kuu jooksul pärast komisjoni otsust.
English: The marketing authorisation holders shall complete the below conditions, within the stated timeframe, and competent authorities shall ensure that the following is fulfilled:
Estonian: Müügilubade hoidjad peavad täitma sätestatud tähtajaks allpool esitatud tingimused ja pädev asutus peab tagama tingimuste täitmise.
English: All MAHs should have in place a Risk management plan (RMP).
Estonian: Peale selle peab kõigil müügilubade hoidjatel olema kehtestatud riskijuhtimiskava.
English: With regards to the studies abovementioned, the MAHs are strongly encouraged to collaborate and perform joint studies.
Estonian: Seoses eespool nimetatud uuringutega soovitatakse müügilubade hoidjatel tungivalt teha koostööd ja korraldada ühisuuringud.
English: The details of the visual reminder should be agreed at national level and be subject to a user test taking into account input from local patient representatives.
Estonian: Visuaalse meelespea üksikasjad tuleb kokku leppida riiklikul tasandil, seda peab eelnevalt katsetama kasutajatel ning arvestada tuleb kohalike patsiendiesindajate sisendinfoga.
English: These materials should ensure that prescriber are informed and the patients understand and acknowledge the risks associated with valproate in-utero exposure.
Estonian: Sellega tagatakse, et ravimi määrajad teavad ning patsiendid mõistavad ja teadvustavad valproaadi üsasisesest ekspositsioonist tulenevaid riske.
English: The MAHs of medicinal products with substances related to valproate shall develop and submit educational materials according to agreed core elements.
Estonian: Valproaati ja sarnaseid nimetusi sisaldavate ravimite müügilubade hoidjad töötavad välja ja esitavad teabematerjali vastavalt kokkulepitud põhipunktidele.
English: The MAHs of medicinal products with substances related to valproate shall conduct a PASS preferably based on existing registries to further characterise the foetal anticonvulsant syndrome in children with valproate in utero exposure as compared to other anti-epileptic drugs.
Estonian: Valproaati ja sarnaseid nimetusi sisaldavate ravimite müügilubade hoidjad teevad turuletulekujärgse ohutusuuringu, mis eelistatavalt põhineb olemasolevatel registritel, et täpsemalt iseloomustada loote antikonvulsandi sündroomi valproaadi üsasisese ekspositsiooniga lastel võrreldes teiste antiepileptiliste ravimite ekspositsiooniga.
English: The MAHs of medicinal products with substances related to valproate shall conduct an observational study to evaluate and identify the best practices for switching of valproate in clinical practice.
Estonian: Valproaati ja sarnaseid nimetusi sisaldavate ravimite müügilubade hoidjad peavad tegema jälgimisuuringu, et hinnata ja identifitseerida valproaatravi vahetamise parimad tavad kliinilises praktikas.
English: The MAHs of medicinal products with substances related to valproate shall conduct a retrospective observational study to investigate the association between paternal exposure to valproate and the risk of congenital anomalies and neurodevelopmental disorders including autism in offspring.
Estonian: Valproaati ja sarnaseid nimetusi sisaldavate ravimite müügilubade hoidjad teevad retrospektiivse jälgimisuuringu, et uurida isapoolse valproaadiekspositsiooni ja kaasasündinud anomaaliate ja neuroloogilise arengu häirete, sealhulgas autismi vahelist seost järglastel.
English: The MAHs of medicinal products with substances related to valproate shall perform a drug utilisation study to assess the effectiveness of the new risk minimisation measures and to further characterise the prescribing patterns for valproate.
Estonian: Valproaati ja sarnaseid nimetusi sisaldavate ravimite müügilubade hoidjad peavad korraldama ravimite kasutamise uuringu, et hinnata uute riskivähendusmeetmete efektiivsust ja täpsemalt iseloomustada valproaadi määramise praktikat.
English: The MAHs of medicinal products with substances related to valproate shall perform a survey among patients to assess knowledge of the patients with regards to PPP as well as receipt/use of educational materials.
Estonian: Valproaati ja sarnaseid nimetusi sisaldavate ravimite müügilubade hoidjad teevad patsientide seas uuringu, milles hinnatakse patsientide teadmisi ja käitumist seoses raseduse ennetamise programmiga ning ka teabematerjalide kättesaamist/kasutamist.
English: MAHs are encouraged to extend the ongoing drug utilisation study (DUS).
Estonian: Müügiloa hoidjatel soovitatakse pikendada käimasolevat ravimikasutusuuringut.
English: A visual reminder on the outer package to warn patient about the harm to unborn baby and the need for effective contraception when using the medicinal product should be implemented in all medicinal products containing substances related to valproate.
Estonian: Kõigi valproaati ja sarnaseid nimetusi sisaldavate ravimite välispakendil peab olema visuaalne meelespea, mis hoiatab patsiente kahjudest sündimata lapsele ja annab teada vajadusest ravimi kasutamise ajal kasutada efektiivset rasestumisvastast meetodit.
English: The MAHs of medicinal products with substances related to valproate shall perform a survey among HCP to assess knowledge of HCP and behaviour with regard to PPP as well as receipt/use of DHPC and educational materials.
Estonian: Valproaati ja sarnaseid nimetusi sisaldavate ravimite müügilubade hoidjad teevad tervishoiutöötajate seas uuringu, milles hinnatakse tervishoiutöötajate teadmisi ja käitumist seoses raseduse ennetamise programmiga ning ka ühise tervishoiutöötajate teatise ja teabematerjalide kättesaamist/kasutamist.
English: ATCvet code: QI09AL
Estonian: ATCvet kood: QI09AL
English: Date of first authorization: 06/11/2015.
Estonian: Esmase müügiloa väljastamise kuupäev: 06.11.2015.
English: Each dose (2 ml) contains:
Estonian: Üks annus (2 ml) sisaldab:
English: Use vaccination devices according to the manufacturer's instructions.
Estonian: Vaktsineerimisseadmeid kasutada tootja juhiste järgi.
English: The vaccine is to be administered aseptically.
Estonian: Vaktsiini peab manustama aseptiliselt.
English: Store and transport refrigerated (2 °C - 8 °C).
Estonian: Hoida ja transportida külmas (2 ºC-8 ºC).
English: Shelf life of the veterinary medicinal product as package for sale: 18months.
Estonian: Müügipakendis veterinaarravimi kõlblikkusaeg: 18 kuud.
English: 125 doses
Estonian: 125 annust
English: Zoetis WHC 2 LLC 2000 Rockford Road, Charles City IA 50616 USA
Estonian: Zoetis WHC 2 LLC 2000 Rockford Road, Charles City IA
English: The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Estonian: Abiained (kaasa arvatud adjuvandid), mis on loetletud ravimi omaduste kokkuvõtte lõigus 6.1, on kas lubatud ained, millele Komisjoni määruse (EL) nr 37/2010 lisa tabelis 1 viidatakse kui ravimjääkide piirnorme mittenõudvatele, või Määruse (EÜ) nr 470/2009 reguleerimisalasse mittekuuluvad, kui neid kasutatakse nii nagu selles veterinaarravimis.
English: During Storage, a slight black deposit may appear and the emulsion may separate into two distinct phases.
Estonian: Säilitamise ajal võib ilmuda kerge must sade ja emulsioon võib jaguneda kaheks eristuvaks faasiks.
English: Pharmacotherapeutic group: immunologicals for Suidae, inactivated viral and inactivated bacterial vaccines for pigs.
Estonian: Farmakoterapeutiline rühm: immunoloogilised ained sigalastele, inaktiveeritud viirus- ja baktervaktsiinid sigadele.
English: Squalane Poloxamer 401 Polysorbate 80
Estonian: skvalaan poloksameer 401 polüsorbaat 80
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Estonian: Kõrvaltoimete esinemissagedus on defineeritud järgnevalt: - väga sage (kõrvaltoime(d) ilmnes(id) rohkem kui 1-l loomal 10-st ravitud loomast) - sage (rohkem kui 1-l, kuid vähem kui 10-l loomal 100-st ravitud loomast) - aeg-ajalt (rohkem kui 1-l, kuid vähem kui 10-l loomal 1000-st ravitud loomast) - harv (rohkem kui 1-l, kuid vähem kui 10-l loomal 10 000-st ravitud loomast) - väga harv (vähem kui 1-l loomal 10 000-st ravitud loomast, sealhulgas üksikjuhud).
English: Incompatibilities: Do not mix with any other vaccine or immunological product.
Estonian: Sobimatus Mitte segada teiste vaktsiinide või immunoloogiliste preparaatidega.
English: Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the vial after EXP.
Estonian: Ärge kasutage veterinaarravimit pärast kõlblikkusaega, mis on märgitud sildil ja kartongkarbil pärast „Kõlblik kuni/EXP”.
English: The vaccine also contains inactivated Mycoplasma hyopneumoniae.
Estonian: Vaktsiin sisaldab ka inaktiveeritud Mycoplasma hyopneumoniae'd.
English: Adjuvant:
Estonian: Adjuvandid:
English: 10 x 25 doses 10 x 50 doses 4 x 125 doses
Estonian: 10 × 25 annust 10 × 50 annust 4 × 125 annust
English: Inactivated Mycoplasma hyopneumoniae, strain P-5722-3
Estonian: Inaktiveeritud Mycoplasma hyopneumoniae, tüvi P-5722-3
English: Administer one dose of 2 ml to pigs in the neck behind the ear.
Estonian: Manustada sigadele üks 2 ml annus kõrva taha kaela.
English: In individual pigs the temperature increase compared to pre-treatment may commonly exceed 2°C.
Estonian: Mõnel seal võib kehatemperatuuri tõus võrreldes ravieelsega sageli ületada 2 °C.
English: Duration of immunity: 23 weeks after vaccination
Estonian: 23 nädalat pärast vaktsineerimist
English: Special warnings for use in animals: Vaccinate only healthy animals.
Estonian: Erihoiatused kasutamisel loomadel Vaktsineerida ainult terveid loomi.
English: Pigs (for fattening).
Estonian: Siga (nuumsead).
English: In the case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Estonian: Ettevaatusabinõud veterinaarravimit loomale manustavale isikule Juhuslikul ravimi süstimisel iseendale pöörduda viivitamatult arsti poole ja näidata pakendi infolehte või pakendi etiketti.
English: A transient increase in body temperature (on average 0.8°C) was observed 4 hours after administration of a 2-fold overdose.
Estonian: 4 tundi pärast kahekordse üleannuse manustamist täheldati mööduvat kehatemperatuuri tõusu (keskmiselt 0,8 °C).
English: In a laboratory study, a post-mortem examination of the injection site, performed 4 weeks after the administration of a single dose of the vaccine, revealed a mild inflammatory response, as evidenced by the absence of tissue necrosis and little fibrosis.
Estonian: Paiksete koereaktsioonide läbimõõt on tavaliselt alla 2 cm. Laboratoorsel katsel näitas 4 nädalat pärast ühe vaktsiiniannuse manustamist läbi viidud tapajärgne süstekoha uurimine kerget põletikureaktsiooni, millest andsid tunnistust kudede kärbumise puudumine ja vähene sidekoestumine.
English: It is intended to stimulate active immunity against PCV2 and Mycoplasma hyopneumoniae in pigs.
Estonian: See on mõeldud sigadel PCV2 ja Mycoplasma hyopneumoniae vastase aktiivse immuunsuse stimuleerimiseks.
English: For active immunisation of pigs from 3 weeks of age against Porcine Circovirus type 2 (PCV2) to reduce viral load in blood and lymphoid tissues and fecal shedding caused by infection with PCV2.
Estonian: Sigade aktiivseks immuniseerimiseks alates 3. elunädalast sigade tsirkoviiruse tüüp 2 (PVC2) vastu, et vähendada PVC2-ga nakatumisest põhjustatud vere ja lümfikoe viiruskoormust ning roojaga eritamist.
English: 25 doses 50 doses
Estonian: 25 annust 50 annust